Agnitio Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AGNITIO
AGNITIO has three approved drugs.
Summary for Agnitio
| US Patents: | 0 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 3 |
Drugs and US Patents for Agnitio
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agnitio | TRIAMTERENE | triamterene | CAPSULE;ORAL | 211581-002 | Aug 19, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Agnitio | PHYTONADIONE | phytonadione | TABLET;ORAL | 213336-001 | Oct 12, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Agnitio | ETHACRYNIC ACID | ethacrynic acid | TABLET;ORAL | 211809-001 | Jul 12, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Agnitio | TRIAMTERENE | triamterene | CAPSULE;ORAL | 211581-001 | Aug 19, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
